We are live on !
Find out more
SL
Siren LLC Portfolio holdings
AUM
$4.94B
Turnover
27.78%
1-Year Est. Return
244.43%
This Fund
S&P 500
This Quarter Est. Return
+34.74%
1 Year Est. Return
+244.43%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$4.94B
AUM Growth
+$1.33B
(+37%)
Cap. Flow
+$314M
Cap. Flow % of AUM
Cap. Flow %
6.35%
Top 10 Holdings %
Top 10 Hldgs %
44.63%
Holding
126
New
26
Increased
32
Reduced
21
Closed
9
Avg Time Held
Equity + Options
0.9
years
Top 10 Avg Time Held
Equity + Options
0.9
years
Top 20 Avg Time Held
Equity + Options
0.7
years
Avg Time Held Equity only
0.9
years
Top 10 Avg Time Held Equity only
0.9
years
Top 20 Avg Time Held Equity only
0.7
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
PBLS
Parabilis Medicines Inc
PBLS
|
+$82.7M |
| 2 |
Abivax
ABVX
|
+$65.2M |
| 3 |
Hemab Therapeutics
COAG
|
+$57.6M |
| 4 |
Relay Therapeutics
RLAY
|
+$53M |
| 5 |
Kailera Therapeutics
KLRA
|
+$48.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Scholar Rock
SRRK
|
+$60.4M |
| 2 |
Edgewise Therapeutics
EWTX
|
+$42.9M |
| 3 |
CNTA
Centessa Pharmaceuticals
CNTA
|
+$41.8M |
| 4 |
Revolution Medicines
RVMD
|
+$30.8M |
| 5 |
Kymera Therapeutics
KYMR
|
+$21.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 92.94% |
| 2 | Technology | 3.57% |
| 3 | Communication Services | 1.85% |
| 4 | Financials | 0.87% |
| 5 | Consumer Discretionary | 0.43% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
|
1
Scholar Rock
SRRK
$5.54B
| $527M | 10.66% |
9,575,013
-1,250,000
| -12% | -$60.4M |
2024 Q3
7 quarters
|
|
|
2
Kymera Therapeutics
KYMR
$11.6B
| $337M | 6.81% |
2,935,830
-251,000
| -8% | -$21.6M |
2024 Q3
7 quarters
|
|
3
Erasca
ERAS
$4.64B
| $209M | 4.23% |
11,397,781
+153,535
| +1% | +$2.2M |
2024 Q3
7 quarters
|
|
4
Veradermics Inc
MANE
$5.7B
| $204M | 4.12% |
1,655,374
+150,000
| +10% | +$14.1M |
2026 Q1
1 quarter
|
|
5
Tango Therapeutics
TNGX
$3.91B
| $193M | 3.91% |
6,179,364
+522,259
| +9% | +$12.9M |
2024 Q3
7 quarters
|
|
|
6
Revolution Medicines
RVMD
$38.1B
| $169M | 3.41% |
900,000
-210,980
| -19% | -$30.8M |
2024 Q3
7 quarters
|
|
7
Bicara Therapeutics
BCAX
$542M
| $166M | 3.37% |
5,602,970
-200,000
| -3% | -$4.46M |
2024 Q3
7 quarters
|
|
8
Arrowhead Research
ARWR
$8.12B
| $140M | 2.83% |
1,715,476
+100,000
| +6% | +$7.39M |
2024 Q3
7 quarters
|
|
9
BeOne Medicines Ltd
ONC
$43.8B
| $133M | 2.68% |
465,000
| – | – |
2024 Q3
7 quarters
|
|
|
10
Edgewise Therapeutics
EWTX
$4.08B
| $129M | 2.62% |
3,184,629
-1,245,634
| -28% | -$42.9M |
2024 Q3
7 quarters
|
|
11
Rhythm Pharmaceuticals
RYTM
$7.28B
| $126M | 2.55% |
1,136,275
+410,764
| +57% | +$37.1M |
2025 Q1
5 quarters
|
|
12
Lexicon Pharmaceuticals
LXRX
$716M
| $106M | 2.15% |
44,303,518
| – | – |
2024 Q3
7 quarters
|
|
13
Enliven Therapeutics
ELVN
$3.46B
| $90.1M | 1.82% |
1,774,411
+1,028,185
| +138% | +$43.7M |
2026 Q1
1 quarter
|
|
14
Spyre Therapeutics
SYRE
$9.41B
| $86M | 1.74% |
968,598
+150,000
| +18% | +$10.9M |
2024 Q4
6 quarters
|
|
|
PBLS
15
Parabilis Medicines Inc
PBLS
$3.75B
| $81.9M | 1.66% |
+2,992,259
| New | +$82.7M |
2026 Q2
0 quarters
|
|
16
Xenon Pharmaceuticals
XENE
$3.65B
| $79.6M | 1.61% |
1,318,564
| – | – |
2024 Q3
7 quarters
|
|
17
Solid Biosciences
SLDB
$663M
| $76.8M | 1.55% |
7,690,405
| – | – |
2024 Q3
7 quarters
|
|
|
18
Abivax
ABVX
$7.37B
| $76.8M | 1.55% |
+576,000
| New | +$65.2M |
2026 Q2
0 quarters
|
|
|
19
Hemab Therapeutics
COAG
$2.11B
| $76.6M | 1.55% |
+2,086,834
| New | +$57.6M |
2026 Q2
0 quarters
|
|
20
Arcus Biosciences
RCUS
$2.25B
| $74.6M | 1.51% |
2,420,430
-586,647
| -20% | -$14.5M |
2024 Q3
7 quarters
|
|
21
Cogent Biosciences
COGT
$5.13B
| $72M | 1.46% |
1,859,279
+150,000
| +9% | +$5.25M |
2025 Q2
4 quarters
|
|
|
22
Relay Therapeutics
RLAY
$3.73B
| $68.3M | 1.38% |
+3,650,000
| New | +$53M |
2026 Q2
0 quarters
|
|
23
Taysha Gene Therapies
TSHA
$1.42B
| $67.1M | 1.36% |
9,846,579
+1,016,666
| +12% | +$6.02M |
2024 Q3
7 quarters
|
|
24
Definium Therapeutics
DFTX
$4.08B
| $66.8M | 1.35% |
1,419,493
+500,000
| +54% | +$12.4M |
2025 Q4
2 quarters
|
|
25
Stoke Therapeutics
STOK
$1.78B
| $65.3M | 1.32% |
1,995,347
| – | – |
2024 Q4
6 quarters
|
|
Similar funds
Siren LLC's Q2 2026 Portfolio in Review
As of Q2 2026, Siren LLC held 126 positions worth $4.94B, up 37% from $3.61B the previous quarter. Its ten largest holdings account for 45% of the portfolio.
Siren LLC deployed $314M of net new capital in Q2 2026, opening 26 new positions and adding to 32 existing holdings. Its largest new stake was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
By sector, the portfolio is most concentrated in Healthcare at 93% of assets, down from 94% a quarter earlier, followed by Technology and Communication Services.
On the sell side, the largest reduction was Scholar Rock, an estimated $60.4M trimmed.
- Siren LLC's largest Q2 2026 buy was Parabilis Medicines Inc: 2,992,259 shares worth $81.9M.
- Siren LLC added most to Enliven Therapeutics in Q2 2026, an estimated $43.7M increase.
- Siren LLC's biggest Q2 2026 reduction was Scholar Rock, cutting an estimated $60.4M.
- Siren LLC fully exited Centessa Pharmaceuticals in Q2 2026, selling an estimated $41.8M.
- Siren LLC's ten largest holdings make up 45% of its $4.94B portfolio in Q2 2026.
- Siren LLC opened 26 new positions and closed 9 in Q2 2026.
- Siren LLC's portfolio value rose 37% quarter-over-quarter to $4.94B.
Based on Siren LLC's 13F filing for Q2 2026, filed 13 Aug 2026.